05.10.2021

Crafting a Cure for Diabetic Neuropathic Pain, Molecule by Molecule (Published by NIH)

A team of scientists at Knopp Biosciences LLC is innovating treatments to manage neuropathic pain by aiming at its source — hyperactive nerve cells.

Read the entire article from the NIH here!

FacebookTwitterLinkedIn

Keep reading

02.28.22

Knopp Biosciences Presents New Phase 2 Data at AAAAI 2022 demonstrating that oral dexpramipexole improves airflow obstruction as measured by forced expiry volume (FEV1), largely through its effect on forced vital capacity (FVC)

Discover this News

02.25.22

Biohaven Acquires Kv7 Ion Channel Platform For The Treatment Of Epilepsy And Other Neurologic Disorders From Channel Biosciences, A Subsidiary Of Knopp Biosciences

Discover this News

10.20.21

Knopp Biosciences NIH-funded Pain Program Advances to Third Year of HEAL Award to Discover Non-Opioid Treatments for Chronic Pain

Discover this News

10.08.21

Phase 2 Trial Evaluating the Effect of Dexpramipexole on Eosinophil Biomarkers and Lung Function in Asthma

Discover this News

09.07.21

Knopp Biosciences Presents New Phase 2 Data at ERS 2021 Demonstrating that Reduction in Eosinophil Count by Dexpramipexole Significantly Correlates with Improvement in Lung Function

Discover this News